Estándar de tratamiento en primera línea de cáncer de páncreas metastásico: ¿ABRAXANE-GEMCITABINA o FOLFIRINOX? - page 16

FOLFIRINOX en práctica clínica habitual

Maroun J et al. ESMO 2015: 302P

N 224

>75 años 7%

PS2 4%

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,6,7,8,9,10,11,12,13,14,15 17,18,19,20,21,22